Positive impactCorporate Action
Avience Biomedicals shares may make a strong debut as GMP signals 62% premium ahead of listing
Economic Times 25 Jun·25 Jun 2026, 2:03 am
The Rs 30.24 crore IPO, which comprised entirely a fresh issue of 14.54 lakh shares, witnessed overwhelming investor interest during the three-day bidding period. The issue was subscribed 385.32 times, driven by robust participation across all investor categories.
Stocks in this story
Avience Biomedicals₹322.30▼ 22.33%
Key takeaways
- Concerns Avience Biomedicals (AVIENCE).
- Category: Corporate Action.
- AI reads the tone as positive (potentially bullish) for the stock.
Why it matters
A routine update for Avience Biomedicals. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
